{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T00:51:13Z","timestamp":1794271873990,"version":"4.9.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005677","name":"Jos\u00e9 Carreras Leuk\u00e4mie-Stiftung","doi-asserted-by":"publisher","award":["AH06-01"],"award-info":[{"award-number":["AH06-01"]}],"id":[{"id":"10.13039\/501100005677","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"Introduction<\/jats:title>The prognosis of anaplastic thyroid carcinoma (ATC) remains poor. Mutation-based targeted therapies and immune checkpoint inhibitors (ICI) have gained increasing importance in the treatment of advanced tumor stages. This study aimed to investigate whether mutation-based neoadjuvant therapy can convert an initially unresectable tumor into a resectable state, optimizing local tumor control and prolonging overall survival.<\/jats:p><\/jats:sec>Methods<\/jats:title>Patients with stages IVB and limited IVC BRAFV600E<\/jats:italic>-negative ATC received immediate combination therapy consisting of the multikinase inhibitor (mKI) lenvatinib and the immune checkpoint inhibitor (ICI) pembrolizumab upon diagnosis. Patients with BRAFV600E<\/jats:italic>-positive tumors were treated with a BRAF\/MEK inhibitor regimen, consisting of dabrafenib and trametinib. This neoadjuvant therapy was administered for 4\u20136 weeks before re-staging. If FDG-PET\/CT imaging demonstrated tumor regression, surgical resection of the primary tumor was performed. In cases of limited distant metastases, these were also surgically removed. In the adjuvant setting, mutation-based systemic therapy was continued.<\/jats:p><\/jats:sec>Results<\/jats:title>Between December 2021 and December 2024, a total of 14 patients were screened. Ultimately, 12 patients, with a median age of 73 years (range: 54\u201385), were treated with neoadjuvant therapy. At diagnosis, six patients had UICC stage IVB and six stage IVC ATC. A BRAFV600E-mutation was detected in two patients. Following neoadjuvant therapy, eight patients showed tumor regression, whereas three exhibited an inadequate response, characterized by disease progression or a mixed response on FDG-PET\/CT. In one patient, therapy was discontinued early due to severe local symptoms. During neoadjuvant treatment, two cases of tracheoesophageal or tracheocutaneous fistulas were observed. Surgical resection was performed in nine patients. An R0 resection was achieved in two, an R1 resection in six, and an R2 resection in one patient. The median follow-up period was eight months (range 1\u201336). Median progression-free survival (PFS) was three months (range 1\u2013not reached), while median overall survival (OS) was nine months (range 1\u2013not reached).<\/jats:p><\/jats:sec>Conclusion<\/jats:title>Neoadjuvant therapy for advanced ATC appears to be a promising treatment approach for a subset of affected patients. While initial results are encouraging, further research is needed to establish its precise role within the multimodal management of this aggressive malignancy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1619875","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T04:11:06Z","timestamp":1756095066000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Mutation-based, neoadjuvant treatment for advanced anaplastic thyroid carcinoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Sabine","family":"W\u00e4chter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Detlef K.","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Riera","family":"Knorrenschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Pehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Eilsberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Pfestroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Luster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Holzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Maurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0944","article-title":"2021 american thyroid association guidelines for management of patients with anaplastic thyroid cancer","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid: Off J Am Thyroid Assoc"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2015.0139","article-title":"Anaplastic thyroid carcinoma, version 2.2015: clinical practice guidelines in oncology HHS public access","volume":"13","author":"Haddad","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-020-05853-8","article-title":"Anaplastic thyroid carcinoma: changing trends of treatment strategies and associated overall survival","volume":"277","author":"W\u00e4chter","year":"2020","journal-title":"Eur Arch Oto-rhino-laryngology: Off J Eur Fed Oto-Rhino-Laryngol Societies (EUFOS): Affiliated German Soc Oto-Rhino-Laryngol Head Neck Surg"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-013-1057-6","article-title":"German Association of Endocrine Surgeons practice guideline for the surgical management of Malignant thyroid tumors","volume":"398","author":"Dralle","year":"2013","journal-title":"Langenbecks Arch Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4742-6","article-title":"Impact of timeliness of resection and thyroidectomy margin status on survival for patients with anaplastic thyroid cancer: an analysis of 335 cases","volume":"22","author":"Goffredo","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20936","article-title":"Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors","volume":"103","author":"Kebebew","year":"2005","journal-title":"Cancer"},{"key":"B7","article-title":"The incidence and survival analysis for anaplastic thyroid cancer: a SEER database analysis","volume":"11","author":"Lin","year":"2019","journal-title":"Am J Trans Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","article-title":"Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019","volume":"6","author":"Maniakas","year":"2020","journal-title":"JAMA Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.06.044","article-title":"Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)","author":"Higashiyama","year":"2022","journal-title":"Eur J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0322","article-title":"Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma","volume":"31","author":"Dierks","year":"2021","journal-title":"Thyroid"},{"key":"B11","doi-asserted-by":"publisher","first-page":"6514","DOI":"10.1200\/JCO.2020.38.15_suppl.6514","article-title":"Atezolizumab combinations with targeted therapy for anaplastic thyroid carcinoma (ATC)","volume":"38","author":"Cabanillas","year":"2020","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/S00405-023-07827-Y","article-title":"Mutation-based, short-term \u201cneoadjuvant\u201d treatment allows resectability in stage IVB and C anaplastic thyroid cancer","volume":"280","author":"Maurer","year":"2023","journal-title":"Eur Arch oto-rhino-laryngology: Off J Eur Fed Oto-Rhino-Laryngol Societies (EUFOS): Affiliated German Soc Oto-Rhino-Laryngol Head Neck Surg"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14679","article-title":"Mutation based approaches to the treatment of anaplastic thyroid cancer","volume":"96","author":"McCrary","year":"2022","journal-title":"Clin Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0133","article-title":"Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAF V600E -mutated anaplastic thyroid carcinoma","volume":"29","author":"Wang","year":"2019","journal-title":"Thyroid"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.05.04","article-title":"Surgery after BRAF-directed therapy is associated with improved survival in BRAFV600E mutant anaplastic thyroid cancer: A single-center retrospective cohort study","volume":"33","author":"Zhao","year":"2023","journal-title":"Thyroid"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann Surg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s44178-022-00016-7","article-title":"A systematic review of neoadjuvant targeted therapy in locally advanced thyroid cancer","volume":"1","author":"Huang","year":"2022","journal-title":"Holist Integ Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s13691-016-0257-7","article-title":"Common carotid artery rupture during treatment with lenvatinib for anaplastic thyroid cancer","volume":"5","author":"Obata","year":"2016","journal-title":"Int Cancer Conf J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.13537","article-title":"Clinical characteristics associated with lenvatinib-induced fistula and tumor-related bleeding in patients with thyroid cancer","volume":"39","author":"Staub","year":"2019","journal-title":"Anticancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"074","DOI":"10.23937\/2378-3419\/3\/6\/1074","article-title":"Massive arterial bleeding after lenvatinib therapy for thyroid cancer","volume":"3","author":"Suyama","year":"2016","journal-title":"Int J Cancer Clin Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0598","article-title":"Aerodigestive fistula formation as a rare side effect of antiangiogenic tyrosine kinase inhibitor therapy for thyroid cancer","volume":"24","author":"Blevins","year":"2014","journal-title":"Thyroid"},{"key":"B23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1159\/000514182","article-title":"Prevalence and risk factors of developing fistula or organ perforation in patients treated with lenvatinib for radioiodine-refractory thyroid cancer","volume":"10","author":"Valerio","year":"2021","journal-title":"Eur Thyroid J"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1619875\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T04:11:07Z","timestamp":1756095067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1619875\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":23,"alternative-id":["10.3389\/fendo.2025.1619875"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1619875","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fendo.2025.1619875.s001","asserted-by":"subject"}]},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"article-number":"1619875"}}